Endomag's Sentimag

Endomag’s Sentimag trial begins in the US

Tuesday, 27 January, 2015

Endomag, the cancer healthcare company, today announced the completion of the first procedures in the USA using its Sentimag® and Sienna+® system for staging breast cancer, marking the start of its pivotal clinical trial.

The study is being led by the University of California San...

Dr Eric Mayes

Endomag to present at influential OneMedForum in San Francisco

Monday, 5 January, 2015

Endomag, the cancer healthcare company, will be presenting plans for its global expansion at the OneMedForum this month.

The influential event is organised alongside the largest gathering of healthcare financiers and executives and will feature a host of emerging life science companies...


Endomagnetics becomes Endomag as business expands into new markets

Thursday, 11 December, 2014

Endomagnetics is today revealing a new brand identity that accurately reflects its position as a global leader in the development of devices for cancer care based on the application of advanced magnetic technologies. 


The identity for newly named Endomag has been built around the...

Endomag icon

Endomagnetics receives IDE approval to initiate US trials

Monday, 1 December, 2014

Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag® and Sienna+®...


Endomagnetics Raises Further Funding for US Clinical Trial, Sales Support and New Product Development

Wednesday, 19 November, 2014

Endomagnetics, the Cambridge-based cancer healthcare company, has raised a further £2m ($3.12m US) to support its pivotal US clinical trial and the launch of a new cancer marker product in 2015.

The funds will also support market development beyond EMEA and Australasia, where the company...


Please select if you are based outside the U.S.A.


Endomag US

Please select if you are based in the U.S.A.